• Skip to main content
  • Skip to primary sidebar
Transfusion News
  • About Us
  • Topics
    • Adverse Events (non-infectious)
    • Blood Donation
    • Cell Therapy
    • Coagulation & Plasma Transfusion
    • Platelet Transfusion
    • Policy and Guidelines
    • Quality Control and Regulatory
    • RBC Transfusion
    • Serology/Genotyping
    • Special Transfusion Situations
    • Transfusion Transmitted Infections
  • Continuing Education
  • Archives
  • Podcasts
  • Question of the Day
  • Search
  • Subscribe to Email Alerts
  • Follow us on
  • Search
  • Subscribe to Email Alerts

Gene Therapy for β-Thalassemia Patients who Are Transfusion Dependent

April 25, 2018

β-thalassemia is one of the most common genetic diseases—especially in North Africa, the Middle East and Asia.  About 60-80% of β-thalassemia patients require frequent red blood cell transfusions and iron chelation, and many of these patients suffer from severe complications of treatment.  Currently, the only curative treatment is allogeneic hematopoietic-cell transplantation, but this treatment has severe side effects. In 2010, the first β-thalassemia patient was successfully treated with gene therapy.  This month, The New England Journal of Medicine reported successful treatment of 22 β-thalassemia patients (12 to 35 years of age) with a lentivirus vector derived from the first patient.  Autologous CD34+ cells from each patient were transduced ex vivo with the lentivirus vector and then reinfused.  After a median of 26 months (range: 15-42 months), 12 of 13 patients with less severe forms of β-thalassemia (non-β°/β°) did not need transfusions, and in the 9 patients with a more severe form of the disease (β°/β° or equivalent) transfusion volume decreased by 73%.  Several patients’ hemoglobin levels also approached normal ranges.  No adverse events directly related to the vector were reported.  Researchers plan to follow the patients for another 13 years.

References:

  1. Thopmson AA, Walters MC, Kwiatkowski J, et al. Gene therapy in patients with transfusion-dependent β-thalassemia. The New England Journal of Medicine 2018; 378(16); 1479-1493.
  2.  A Biffi. Gene therapy as a curative option for β-thalassemia. The New England Journal of Medicine 2018; 378(16); 1551-1552.

Filed Under

  • Cell Therapy
  • News

Recommended

  • Transfusing Individuals with Asian-type DEL Rh Antigen

  • Dithiothreitol (DTT)-based Method Validated for Blood Compatibility Testing in Patients Taking Daratumumab

  • Acute Normovolemic Hemodilution Does Not Reduce RBC Transfusions

Show Comments

Comments on this article are closed.

Get the latest news. Subscribe to our mailing list. Sign Up

Primary Sidebar

Latest News

  • Plasma Equivalent to Clotting Factor Concentrates for Initial Resuscitation of Patients with Severe Trauma

  • Personalized Prediction Model of Prophylactic Platelet Transfusions for Preterm Infants

  • Caffeine in Donor Blood Reduces Quality of Stored RBCs

  • Ferritin Levels Needed to Assess Hemoglobin Recovery after Blood Donation

    Question of the Day

    Copyright © 2025 John Wiley & Sons, Inc. All Rights Reserved.
    Privacy Policy

    Association for the Advancement of Blood and Biotherapies Wiley